Rangering i aksjer
#38795
Agentix Corp., a company in the clinical development phase, specializes in the... Agentix Corp., a company in the clinical development phase, specializes in the discovery and commercialization of therapeutic agents aimed at treating metabolic disorders. Its pipeline includes two primary candidates: AGTX-2004, a peripherally-acting CB1 receptor antagonist, which has exhibited effectiveness in animal studies for both obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, also demonstrating positive results in animal models for obesity and non-alcoholic fatty liver diseases. The company was founded in 2013, initially known as FairWind Energy, Inc., before officially changing its name to Agentix Corp. in June 2019. Its operations are based in Dana Point, California.
Aksjekurs
$0.02
Sist synkronisert: 2026-08-13
Handel Agentix Corp. (AGTX)
Pris AGTX pris med markedsverdi på B
Markedsverdi av Agentix Corp.(AGTX)
Markedsverdi: $801.34K
Per August 2026 har Agentix Corp. en markedsverdi på $801.34K. Dette gjør Agentix Corp. til det 38795th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Agentix Corp. fra 2015 til 2026
AGTX sammenlignet med topp 5 mest populære stocks
| Pris på AGTX |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.478T
|
+683,553,196.42%
|
|
|
|
|
$4.488T
|
+560,091,890.75%
|
|
|
|
|
$4.163T
|
+519,563,287.56%
|
|
|
|
|
$3.704T
|
+462,283,450.91%
|
|
|
|
|
$2.841T
|
+354,592,396.43%
|
